U.S. STOCKS ON THE MOVE-Modular Medical, Beazer Homes, oil firms
U.S. STOCKS ON THE MOVE-Hoth Therapeutics, gold miners, Gatos Silver
U.S. STOCKS ON THE MOVE-Tesla, IN8bio, Nio
N8bio falls after suspending development of two brain cancer drugs
Brief: In8bio Announces Clinical Pipeline Prioritization
Brief: In8bio Presents Positive Data Demonstrating Durable 1-Year Complete Remission In 100% Of Evaluable Patients In Phase 1 Trial Of Inb-100
Brief: IN8bio Doses First Patient In Phase 2 Clinical Trial Of INB-400 In Newly Diagnosed Glioblastoma
Brief: IN8bio Announces New Preclinical Data For Gamma-Delta nsCAR-T Cell Therapy Platform At AACR 2024
U.S. RESEARCH ROUNDUP-Cooper Companies, Southwest Airlines, Weyerhaeuser
Brief: Orin Hirschman Reports 9.4% Passive Stake In In8bio
U.S. STOCKS ON THE MOVE-Expedia, Moderna, HubSpot
U.S. STOCKS ON THE MOVE-C4 Therapeutics, Eagle Bulk, SilverBow Resources
U.S. STOCKS ON THE MOVE-Wyndham Hotels, Alphabet, Candel Therapeutics
IN8bio shares surge on positive results from leukemia treatment trial
Brief: In8bio Announces Positive Update In Phase1 Trial Of Inb-100 In Leukemia
Brief: IN8BIO Updated Data From Phase 1 Investigator-Sponsored Trial Of INB-100
Brief: In8bio Inc Increases Board To Eight From Seven Directors
Brief: In8bio's Inb-200 shows Extended Progression-Free Survival In Patients With Newly Diagnosed Glioblastoma
Brief: IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma